Global Biotechnology Contract Manufacturing Market Growth (Status and Outlook) 2024-2030

Global Biotechnology Contract Manufacturing Market Growth (Status and Outlook) 2024-2030

The increasing popularity of biologics in medicine has led to a significant rise in outsourcing manufacturing. Biologics contract manufacturers have the know-how and setup to make these complex therapies effective while ensuring the meeting of strict quality rules and regulations.

The global Biotechnology Contract Manufacturing market size is projected to grow from US$ 17390 million in 2024 to US$ 29390 million in 2030; it is expected to grow at a CAGR of 9.1% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Biotechnology Contract Manufacturing Industry Forecast” looks at past sales and reviews total world Biotechnology Contract Manufacturing sales in 2022, providing a comprehensive analysis by region and market sector of projected Biotechnology Contract Manufacturing sales for 2023 through 2029. With Biotechnology Contract Manufacturing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biotechnology Contract Manufacturing industry.

This Insight Report provides a comprehensive analysis of the global Biotechnology Contract Manufacturing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biotechnology Contract Manufacturing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biotechnology Contract Manufacturing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biotechnology Contract Manufacturing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biotechnology Contract Manufacturing.

According to Statista, there were more than 21,000 drugs in the global R&D pipeline in 2023. Also, the FDA approved 71 new drugs in 2023; out of these, 48% of new approvals were biologics. Moreover, the demand for biologic drug substance contract manufacturing is expected to be the highest among smaller biotech companies that hold intellectual property rights for novel biologics. This has led to the incorporation of cutting-edge production methods like continuous manufacturing and single-use technologies aimed at enhancing operational efficiency and adaptability. Additionally, partnerships and collaborations between pharmaceutical firms and contract manufacturing organizations are increasing for biologic drug product manufacturing, allowing for the modification of manufacturing processes and cost-effective solutions.

This report presents a comprehensive overview, market shares, and growth opportunities of Biotechnology Contract Manufacturing market by product type, application, key players and key regions and countries.

Segmentation by Type:
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing

Segmentation by Application:
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing

Segmentation by Application:
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Thermo Fisher Scientific, Inc.
Catalent, Inc.
Samsung Biologics
WuXi Biologics
Boehringer Ingelheim International GmbH
FUJIFILM Holding Corporation
AbbVie, Inc.
Eurofins Scientific
AGC, Inc.
Merck KgaA

Please note: The report will take approximately 2 business days to prepare and deliver.